Madison Vaccines Incorporated

Showcase Sponsor

Madison Vaccines Incorporated (MVI) is developing two different DNA vaccines to treat prostate cancer patients throughout critical stages of their disease.  MVI-816 is a PAP DNA vaccine progressing in a multi-site Phase 2 clinical trial in non-metastatic, biochemically recurrent prostate cancer.  MVI-816 is also in a Phase 1/2 combination clinical trial with Keytruda® in men with metastatic castrate-resistant prostate cancer.  MVI-118, the only immunotherapy targeting the human androgen receptor, is in a Phase 1 clinical trial in patients with newly metastatic disease who are starting androgen deprivation therapy (ADT), and is intended to prolong the duration of disease control men receive from currently available (ADT).